Compare
Yarrow Bioscience, Inc. vs BioXcel Therapeutics, Inc. vs Scienture Holdings, Inc. vs 60 Degrees Pharmaceuticals, Inc.
| Latest fiscal year | Yarrow Bioscience, Inc. YARW | BioXcel Therapeutics, Inc. BTAIQ | Scienture Holdings, Inc. SCNX | 60 Degrees Pharmaceuticals, Inc. SXTP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $570.0K | $642.0K | $431.6K | $1.01M |
| Revenue growth (YoY) | +13.8% | -71.7% | +215.9% | +65.5% |
| Gross margin | n/a | 74.5% (computed) | 76.8% | 22.3% |
| Operating margin | n/m | n/m | n/m | -771.6% |
| Net margin | n/m | n/m | n/m | -732.5% |
| Net income | -$26.48M | -$69.90M | -$41.51M | -$7.37M |
| EPS (Diluted) | -$0.62 | -$5.73 | -$2.70 | -$11.73 |
| Operating cash flow | -$33.12M | -$57.62M | -$13.38M | -$6.85M |
| Free cash flow | -$33.12M | -$57.62M | n/a | -$6.99M |
| Cash & equivalents | $24.03M | $28.41M | $6.66M | $1.51M |
| Total assets | $30.16M | $44.92M | $84.18M | $5.37M |
| Total liabilities | $2.40M | $140.38M | $14.06M | $1.99M |
| Shareholders' equity | $27.77M | -$95.46M | $70.12M | $3.46M |
| Return on year-end equity | -95.4% | n/a | -59.2% | -212.7% |
| Shares outstanding | 33.32M | 22.33M | 40.63M | 1.16M |
Revenue, most recent five fiscal years
| Fiscal year | Yarrow Bioscience, Inc. | BioXcel Therapeutics, Inc. | Scienture Holdings, Inc. | 60 Degrees Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $570.0K Ended 2025-12-31 | $642.0K Ended 2025-12-31 | $431.6K Ended 2025-12-31 | $1.01M Ended 2025-12-31 |
| 1 year earlier | $501.0K Ended 2024-12-31 | $2.27M Ended 2024-12-31 | $136.6K Ended 2024-12-31 | $607.6K Ended 2024-12-31 |
| 2 years earlier | $424.0K Ended 2023-12-31 | $1.38M Ended 2023-12-31 | $1.36M Ended 2023-12-31 | $253.6K Ended 2023-12-31 |
| 3 years earlier | $477.0K Ended 2022-12-31 | $375.0K Ended 2022-12-31 | $10.25M Ended 2022-12-31 | $223.2K Ended 2022-12-31 |
| 4 years earlier | $931.0K Ended 2021-12-31 | n/a | $9.89M Ended 2021-12-31 | n/a |